Size Exclusion Chromatography of Peptides: Dimers and Aggregates
A reversed-phase purity trace can look excellent while part of the material in the vial is sitting in dimers or larger clusters. The reason is that reversed-phase conditions pull most non-covalent assemblies apart before anything reaches the detector. Size exclusion chromatography of peptides works on a different principle, sorting molecules by their size in solution under mild conditions, so it can reveal aggregates that a purity run never shows. This article explains how the method works, where its numbers can mislead, and when a lab handling multi-vial lots might want it alongside routine testing.
Separating by size instead of stickiness
A size exclusion (SEC) column is packed with porous particles. As a sample moves through, small molecules wander into the pores and take a long, winding route. Larger molecules are shut out of some or all of the pores and pass mainly through the gaps between particles, so they reach the end sooner. The elution order is therefore largest first, smallest last.
Unlike reversed-phase HPLC, nothing is meant to bind to the stationary phase. The mobile phase stays the same composition throughout (isocratic elution), there is no gradient, and the whole separation happens within roughly one column volume of flow. That makes runs quick and comparatively gentle, which is exactly why fragile, non-covalent assemblies survive them.
The usable window: two boundary volumes
Every SEC column has a fixed working range, defined by two volumes:
- Void volume (V0). The elution volume for anything too large to enter the pores at all. Everything bigger than the exclusion limit comes out together here, unseparated.
- Total permeation volume (Vt). The elution volume for molecules small enough to explore every pore. Everything below the lower size limit also comes out together, again unseparated.
Separation only happens between those two points. A column whose pore size is suited to large proteins will push a small peptide and its dimer into the same peak at the total permeation volume. Choosing a column rated for the right size range is the single most important decision in setting up the method, and the usual cause when an SEC run on a small peptide returns one uninformative peak.
Why SEC molecular weights are only apparent
Converting an elution volume into a molecular weight requires a calibration curve built from standards of known mass. The result is properly called an apparent molecular weight, because the column responds to hydrodynamic size (how much space the molecule occupies as it tumbles in solution) rather than to mass itself.
Calibration standards are usually compact, globular proteins. Many peptides are extended and flexible in aqueous buffer, so they occupy more volume than a globular molecule of equal mass, elute earlier and read heavier than they really are. An SEC-derived weight should never be treated as a mass measurement. For that, use mass spectrometry, judged against the accuracy discussed in mass accuracy and peptide identity.
Keeping the column honest: mobile phase and secondary interactions
Ideal SEC relies on size alone. Real packings carry some residual surface charge and some hydrophobic character, and peptides can interact with both. A strongly basic peptide may be held back and elute late, looking smaller than it is. An acidic one may be pushed away from the charged surface and elute early, looking larger.
The usual remedy is a buffered mobile phase with enough salt to damp ionic effects, sometimes with a small proportion of organic solvent to reduce hydrophobic contact. Because these choices change retention, SEC results are only comparable between runs using the same mobile phase, column and flow rate. The charge behaviour behind this is the same one described in isoelectric point and solubility. For a lab trending aggregate levels across many lots, locking the method conditions down is essential.
Size exclusion chromatography of peptides versus reversed-phase
The two techniques answer different questions, which is why they complement each other:
| Reversed-phase HPLC | Size exclusion chromatography | |
|---|---|---|
| Separates by | Hydrophobicity | Hydrodynamic size |
| Conditions | Organic solvent and acid; denaturing | Aqueous buffer near neutral pH; mild |
| Non-covalent dimers and oligomers | Usually broken apart; not seen | Usually preserved; seen as earlier peaks |
| Covalent dimers (e.g. disulfide-linked) | Seen | Seen |
| Deletion and truncation sequences | Well resolved | Generally not resolved (too similar in size) |
| Resolution | High | Low; species need to differ substantially in size |
Because the blind spots barely overlap, the pairing fits the idea of independent confirming methods. The solution behaviour that produces non-covalent aggregates is covered in peptide aggregation in solution.
Detector options
UV absorbance is the default detector, with the response-factor caveats covered in UV response factors; large aggregates can also scatter light and inflate their own signal. A refractive index detector responds more directly to mass but is less sensitive. Adding a multi-angle light scattering (MALS) detector changes the measurement fundamentally: it calculates molar mass from scattered light without relying on a calibration curve, removing the shape assumption, provided an accurate concentration signal runs alongside it.
Pitfalls that make aggregates disappear
- Dilution on the column. The sample spreads out and becomes more dilute as it travels. A weakly held, concentration-dependent oligomer can fall apart during the run and be under-counted or missed.
- Material that never comes off. Aggregates can stick to frits or packing. Compare the total peak area with a reference injection that bypasses the column; missing mass is a finding, not noise.
- Sample clean-up removes the evidence. Filtering or centrifuging before injection strips out insoluble aggregate. The result then describes the soluble fraction only, and the report should say so.
- Limited resolving power. Species that differ in size by less than about a factor of two are hard to separate reliably on a single column.
When SEC belongs in a QC plan
With short synthetic sequences, the most important impurities (deletions, truncations, leftover synthesis reagents) are nearly the same size as the target, so SEC cannot see them while reversed-phase resolves them well. That is why SEC seldom appears on routine certificates for short sequences.
It becomes worthwhile as chains get longer, where structure matters, and where aggregation state is a stability concern. A lab holding a large inventory of a longer or aggregation-prone peptide might run SEC on retained samples from each lot, or on solutions after freeze-thaw cycles or extended storage, to see whether the proportion of monomer is holding steady. Read next to a reversed-phase trace, it answers a separate question: not whether the molecule is correct, but whether the correct molecule is still on its own.
All Bulk Peptides products are supplied for laboratory research and analytical use only and are not intended for human or veterinary use.
